2023 World Conference on Lung Cancer (Posters)-EP12.01. Case Report of Short-Term Gefitinib Induced IgA Nephropathy and Tubulointerstitial Nephritis in a Patient with Non-small Cell Lung Cancer

EP12.01. Case Report of Short-Term Gefitinib Induced IgA Nephropathy and Tubulointerstitial Nephritis in a Patient with Non-small Cell Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

This document is a case report presented at the WCLC 2023 conference. The report discusses a rare adverse effect of a medication called gefitinib, which is commonly used as a targeted therapy for non-small cell lung cancer (NSCLC) with specific mutations. The patient in this case report developed IgA nephropathy and tubulointerstitial nephritis, which are types of kidney disease, after being treated with gefitinib for six weeks. Prior to starting the medication, the patient's renal function was normal. <br /><br />After the kidney injury was diagnosed, gefitinib was discontinued and steroid treatment was initiated. The patient's renal function gradually improved, and they were then treated with another medication called erlotinib for two months. The patient did not experience disease progression, and their renal function returned to normal.<br /><br />The report highlights the rarity of renal failure as an adverse effect of gefitinib and emphasizes the need for further research to better understand and manage kidney injury induced by this type of medication. Overall, this case report provides important insights into a potential side effect of gefitinib therapy and underscores the importance of monitoring renal function in patients receiving targeted therapies for NSCLC.

Asset Subtitle

Jieun Yang

Meta Tag

Speaker Jieun Yang

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

case report

gefitinib

adverse effect

NSCLC

renal function

steroid treatment

erlotinib

renal failure

medication side effect

targeted therapy